invasive breast cancer at their entry into the study. Tamoxifen not only significantly reduced the subsequent occurrence of breast cancer in the treated group as a whole, but remarkably, it was effective in women with a history of lobular carcinoma in situ or atypical hyperplasia, indicating that this agent can prevent the further progression of established preneoplastic lesions in the breast.
The second trial, involving more than 7000 post-menopausal women with known osteoporosis (but with no specific risk factors for breast cancer other than age), showed that raloxifene dramatically decreased risk of development of breast cancer. The third trial, with fenretinide, was conducted in a cohort with particularly high risk, namely women who had undergone surgery for a previous breast cancer and who thus were at malignancy. Although fenretinide treatment had no statistically significant effect in the cohort as a whole on the incidence of a second breast malignancy, the subgroup of pre-menopausal efficacy of this combination for prevention of breast cancer in women treated with fenretinide had a significantly lower women remains to be determined. incidence of new breast cancers than the corresponding control
The major benefits that have been demonstrated clinically group. Since pre-menopausal breast cancer is often characterfor tamoxifen, raloxifene and fenretinide are in marked contrast ized by particularly aggressive invasive and metastatic behavior to the unfortunate results that have been obtained with and is therefore particularly difficult to manage, these results β-carotene in several prevention trials (15) (16) (17) . The failure of with fenretinide are of special interest.
the β-carotene trials represents a good example of the results The importance of the above three trials for the future of of entering putative chemopreventive agents into clinical trials the entire field of chemoprevention cannot be overstated. They before there are adequate mechanistic and animal data to are landmark studies for several reasons. First of all they support their use in men and women. In the case of β-carotene, clearly demonstrate that the most common form of cancer in there were essentially no data from animal studies that this women can be controlled by a preventive approach. Secondly, agent would prevent any important form of cancer in an they demonstrate that a rational approach to prevention, based experimental animal. The impetus to use β-carotene as a on the use of agents whose mechanism of action is understood, chemopreventive agent came from epidemiologic studies, and, can be used to develop drugs for chemoprevention. Thus, both even in these studies, there was no direct evidence that tamoxifen and raloxifene are estrogen receptor antagonists in β-carotene, rather than a large number of other substances the breast, an organ in which estrogen is a known promoting occurring in fruits and vegetables, might be responsible for agent for carcinogenesis. Tamoxifen and raloxifene bind to any benefit (18) . Thus, it is essential to realize that epidemioboth estrogen receptors (ER-α and ER-β). Furthermore, tamoxlogical data alone do not provide a sufficient basis for the selection of a new agent for a major clinical chemoprevention ifen and raloxifene had been conclusively shown to prevent trial. The future of this field will depend on the development breast cancer in experimental animal models before they were of new agents whose mechanism of action is well understood, used clinically for this purpose (8) (9) (10) . Finally, in terms of and we will now turn to a discussion of this problem. their clinical utility, they are good examples of the selective estrogen receptor modulator (SERM) concept, in that they can Chemoprevention based on mechanism act selectively in different tissues and organs either as estrogen antagonists (to suppress the undesirable cancer-promoting
The appropriate use of a chemopreventive agent ultimately effects of estrogen in the breast) or as estrogen agonists (to depends on the understanding of its mechanism of action at enhance the desirable growth-promoting effects of estrogen in all levels, namely at the molecular, cellular, tissue and organ bone). With respect to its overall SERM profile, raloxifene levels, as well as in the animal as a whole. Without this appears to be the superior agent, since it is not uterotrophic knowledge we can only make intuitive decisions in selecting and does not cause endometrial carcinoma, as does tamoxifen.
preventive agents and hope that a useful clinical result will be However, the relative efficacy of tamoxifen and raloxifene in forthcoming. The trend in the field of chemoprevention has preventing breast cancer in a single clinical trial, in which therefore been to develop new agents based on their mechanism they are directly compared, remains to be determined; this is of action, and we will mention four such categories of new presently underway in the 'STAR' trial sponsored by the agents, which hold great promise for eventual clinical use National Cancer Institute.
( Figure 1 ). The third agent, fenretinide, is a synthetic retinoid which Agents in the first category are selective inhibitors of was shown many years ago to be a differentiating agent for inducible cyclooxygenase (COX-2), which is a key enzyme tracheobronchial and mammary epithelium, as well as to be responsible for the synthesis of inflammatory prostaglandins an effective drug for preventing experimental breast cancer from arachidonic acid. Although the concept that inflammation (11). There is abundant literature on the successful use of and carcinogenesis are related processes is by no means new retinoids to prevent cancer at many epithelial target sites in (19) , the immediate relevance of this notion to the world of experimental animals, as well as in humans (12, 13) . Interesmodern molecular genetics was demonstrated by the finding tingly, fenretinide and tamoxifen act synergistically in supthat overexpression of the gene for COX-2 is an early and important event in colon carcinogenesis (20) and that knockout pressing mammary carcinogenesis in rats (14) , although the of the gene for COX-2 could suppress colon carcinogenesis Interestingly, the new rexinoids do not have the classic toxicologic profile of typical retinoids; thus they do not elicit the in mice that were genetically predisposed to develop this condition (21) . This in turn has led to the development of new same sort of mucocutaneous toxicity, and they are very weak teratogens. pharmacologic agents, such as celecoxib (Figure 1) , that are selective for inhibition of the enzymatic activity of COX-2, The orphan nuclear receptor, PPAR-γ, represents another new target for development of ligands for chemoprevention. while not affecting the constitutive form of the enzyme (COX-1). Celecoxib has been shown to prevent colon carcinogenesis PPAR-γ is now an important target for development of drugs that are used to treat type 2 diabetes, such as the thiazolidinecaused by azoxymethane in a standard rat model (22) , and is now in clinical trial in cohorts of patients at high risk, such diones (TZDs), because ligands for PPAR-γ can sensitize cells to the adipogenic action of insulin (35, 36) . Because of the as those with familial adenomatous polyposis or hereditary non-polyposis colorectal cancer syndromes. Hopefully, agents ability of PPAR-γ to bind both fatty acids and prostaglandins, it has also become a target for investigation in colon carcinogenthat are selective for COX-2 inhibition will be much better tolerated during prolonged chronic administration than the esis. Recent studies have led to conflicting results, with two studies (37, 38) showing that the TZD, troglitazone, enhanced non-selective non-steroidal anti-inflammatory drugs (including aspirin) that have been used in the past. The recent demonstracolon carcinogenesis in Min mice (in these mice there has been loss of a single copy of the tumor suppressor APC gene), tion of the overexpression of COX-2 in many other forms of epithelial cancer (23-26) now also offers promise that selective whereas a third study (39) indicated that in cell culture troglitazone suppressed the growth of human colon cancer COX-2 inhibitors might be used to suppress in carcinogenesis in organs other than the colon. cells as well as the expression of several genetic markers associated with colon cancer. Furthermore, other studies have A second category of important new agents are the SERMs. Although tamoxifen and raloxifene are both in clinical use, indicated that troglitazone can induce differentiation in human liposarcoma cells (40). they represent agents that were synthesized Ͼ20 years ago, before the cloning of the estrogen receptors, and before
Because the ability of ligands for PPAR-γ to suppress experimental mammary carcinogenesis had not been investistructural biology has allowed us to make accurate molecular models of the binding of estrogen and estrogen analogs to gated, we chose to study the activity of a member of a new class of PPAR-γ ligands (tyrosine analogs) in the standard rat these receptors. The demonstration of the occurrence of ER-β, as contrasted with ER-α, in the prostate, colon and ovary also system that uses NMU as carcinogen. Accordingly, we have shown recently (41) that the new agent, GW7845 (Figure 1 ), suggest that it may be useful to develop estrogen analogs that will be selective for binding to this isoform (27) . The estrogen which is significantly more active as a PPAR-γ ligand than troglitazone, is highly effective in preventing breast cancer in receptor in the prostate is a particularly interesting target for chemoprevention, and indeed it has already been shown that the rat. Ligands for PPAR-γ have been shown to have marked synergism with rexinoids in treatment of experimental diabetes tamoxifen is a highly effective agent for suppression of experimental prostatic carcinogenesis in the rat (28) . Many (30) . It would now seem reasonable to suggest that similar synergisms between these two classes of agents in chemoprevnew SERMs have been synthesized, but they have yet to be used effectively for chemoprevention. One agent that is highly ention of cancer will also be found. Indeed, it will be surprising if useful chemopreventive synergisms do not exist among all promising is LY353381.HCl (Figure 1) , which is significantly more potent than raloxifene in many assays, including prevenfour classes of agents shown in Figure 1 . Thus, combination chemoprevention, whereby one achieves tion of breast cancer induced in the rat with nitrosomethylurea (NMU) (29) . significant synergism of two or more drugs to obtain a desired preventive effect, while minimizing the toxic side effects of The retinoids that are selective for binding to the three retinoid X receptors (RXRs), whereas not binding to the three the individual components of the combined regimen, represents an important challenge in this entire field. There are numerous retinoic acid receptors (RARs), are now called 'rexinoids' (30) , and represent a third important new category for chemoexamples of such synergy in experimental chemoprevention of cancer (2,4,13), and it is likely that the future practical prevention. The RXRs are of particular importance in the nuclear receptor superfamily because of their ability to heterodevelopment of chemopreventive regimens will rely on the use of this principle. dimerize with many other members of this family, including the RARs, the vitamin D receptor, the thyroid receptor, as well as relatively newly discovered 'orphan' receptors, such as Development of new classes of chemopreventive agents peroxisome proliferator-activated receptor-γ (PPAR-γ), liver X receptor (LXR) and farnesoid X-activated receptor (FXR)
The need for new agents with novel mechanisms of action to prevent cancer is perhaps the most urgent need in the entire (31) (32) (33) . RXRs thus play a central, integrative role in the cellular physiology of the nuclear receptor superfamily by field of chemoprevention. Although proof of principle of chemoprevention has been clearly demonstrated, in both animal virtue of their ability to modulate the activity of many other receptors. It is therefore not surprising that rexinoids have been and clinical studies, none of the existing chemopreventive agents is ideal, either because of lack of efficacy and potency, found to be potent chemopreventive agents in experimental animals. The first of the rexinoids to be used for this purpose or because of toxic side effects that preclude widespread, longterm use. Discovery of new agents is therefore of vital was LGD1069 (targretin) for prevention of mammary carcinogenesis in the rat (34) . However, targretin is not totally specific importance. Overall strategies for new drug discovery in chemoprevention have been reviewed at length elsewhere for binding to RXR, and at high concentrations it will bind to the RARs. Therefore new rexinoids, which have essentially (2,4), and we will not discuss the broader aspects of this problem here. Rather, as a single example of approaches that no affinity for RARs, have been synthesized; LG100268 (Figure 1 ) is a prototype of this new class; it is highly can be taken in this general area, we will briefly summarize some recent attempts in our own laboratory to develop a effective in the rat mammary carcinogenesis prevention model. dammarane, taraxastane, oleanane and friedelane patterns to emphasize the use of various cyclosqualenoid molecules derived from plants as medicinal or antimicrobial agents, as documented at length (42) . For our own research in this area, we have focused on derivatives of either oleanolic acid and ursolic acid (Figure 4 ), since both these agents have been shown to have definite anti-inflammatory and anti-carcinogenic activities (44, 45) , although their potency and efficacy are relatively weak. Our underlying hypothesis has been that the inflammatory process and the carcinogenic process are mechanistically related (19) , and that it should be possible to ability to block the de novo synthesis of two key antiinflammatory enzymes, namely inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2). new class of chemopreventive agents. These new agents are triterpenoids that, together with their close chemical relatives,
We have therefore undertaken a program to synthesize analogs of ursolic and oleanolic acid, and to assay these new the steroids, are members of a larger family of related structures that we would like to call cyclosqualenoids.
derivatives for their ability to suppress the expression of the genes for iNOS and COX-2. Many of these new analogs are In the bacterial, plant and animal worlds, squalene, which is an open-chain 30-carbon isoprenoid molecule, is cyclized significantly more potent than either ursolic or oleanolic acid (46) , and one of them, 2-cyano-3,12-dioxoolean-1,9-dien-28-(either directly, or via its metabolite, 2,3-oxidosqualene) to form tetracyclic or pentacyclic derivatives. There are at least oic acid has shown exceptional activity; it is 1000 times more potent than oleanolic acid in primary mouse macrophages in 20 different folding patterns resulting from this enzymatic cyclization, and each pattern of folding is believed to be suppressing the production of nitric oxide induced by interferon-γ (47) . This new agent also shows interesting activity in catalyzed by a unique enzyme (or set of enzymes), known as cyclases. The most familiar of these cyclization schemes is differentiating a variety of human leukemia cells, as well as blocking the growth of many human cancer cells. Its use as a that which converts squalene to the proximate tetracyclic 30-carbon molecule, lanosterol (Figure 2) , which can then be chemopreventive agent in vivo is presently being evaluated. There is no question that the entire family of cyclosqualenofurther oxidatively and catabolically metabolized to the precursor of all the common steroids, namely cholesterol. Howids represent a fruitful area for future synthesis and development of new chemopreventive agents. The parent structures ever, this well known cyclization of 2,3-oxidosqualene to lanosterol represents only a small fraction of the cyclosquathat are found in plants have been in the biosphere for millions of years, and it is highly likely that evolution has led to some lenoid diversity that exists in nature. Thus, in bacteria and plants there exist thousands of tetracyclic or pentacyclic molecular fit of these agents as ligands for receptors that are found in animals. The development of this area on a mechanistic derivatives of squalene that are not derived from lanosterol (42, 43) . This huge set of cyclosqualenoid molecules has been basis remains an intriguing challenge for the future. derived from squalene by the initial action of a diverse set of cyclases (distinct from the oxidosqualene-lanosterol cyclase), References each of which contributes to the total diversity of the folding patterns that are obtained. We have chosen to show only six
